Irish Medtech Firm’s Digital Solution Shown by Researchers to Reduce Health Service Costs by 92%

Why It Matters

The study provides rare gold‑standard evidence that digital health can slash costs and streamline outpatient care without compromising quality, prompting rapid adoption by major health systems.

Key Takeaways

• Remote monitoring cut outpatient visits by 80% in lung transplant trial
• Health service costs fell 92% versus standard clinic care
• Manchester NHS extended patientMpower to 1,000+ patients after trial
• Solution already used in seven countries, including NYU Langone Health
• Evidence from RCTs boosts clinician confidence in digital health adoption

Pulse Analysis

The latest Manchester‑based randomised controlled trial underscores a turning point for digital health, demonstrating that remote patient monitoring can achieve clinical parity while dramatically reducing resource utilisation. By capturing real‑time physiological data and symptom reports, patientMpower’s platform enables clinicians to intervene early, a capability traditionally reserved for in‑person visits. This evidence base is especially valuable because RCTs are seldom applied to software solutions, lending credibility that can accelerate regulatory acceptance and payer reimbursement.

Cost efficiency is the headline. An 80% cut in outpatient appointments translates into fewer clinic slots, reduced staffing pressures, and lower facility overhead. The 92% cost reduction—derived from fewer appointments, travel savings, and avoided admissions—offers a compelling business case for health systems grappling with budget constraints. Manchester’s decision to renegotiate the contract, extend the solution to over a thousand patients, and embed it within the Epic electronic health record illustrates how proven outcomes can drive rapid scaling and integration into existing workflows.

Beyond lung transplants, patientMpower’s technology is being deployed for heart, kidney and maternity care, positioning it as a versatile tool for chronic disease management. As populations age and the prevalence of long‑term conditions rises, scalable virtual care pathways will become essential to maintain quality while containing costs. The trial’s success may spur further investment in digital therapeutics, encourage other providers to seek RCT validation, and ultimately reshape outpatient models across Europe and North America.